Page 14 - KIDNEY CANCER

Conclusions

• First randomized trial exclusively in metastatic pRCC to

complete accrual

• Cabozantinib demonstrated a prolonged PFS and better

ORR compared to sunitinib across all metastatic pRCC

• PFS 9.0 vs 5.6, HR 0.60 (95%CI 0.37-0.97 [1-sided P-value=0.019])

• ORR 23% vs. 4% [2-sided P-value=0.010])

• Savolitinib and Crizotinib did not show any PFS benefit

• Cabozantinib should be considered the new reference

standard for systemic therapy in patients with metastatic

pRCC